BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
BioCentury | Jan 4, 2019
Clinical News

Sunovion's SEP-363856 meets in Phase II for schizophrenia

...Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in...
...SEP361-201 trial to treat hospitalized patients with acute exacerbations of schizophrenia. On the primary endpoint, SEP-363856...
...NA SEP-363856 is an antipsychotic targeting serotonin (5-HT1A) receptor and trace amine-associated receptor 1 (TAAR1). Brian Moy SEP-363856 PsychoGenics...
BioCentury | Sep 7, 2018
Clinical News

Setback for Sunovion's dasotraline in ADHD

...Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said it received a complete response letter for dasotraline (SEP-225289...
...Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Dasotraline (SEP-225289) Business: Neurology Sandi Wong dasotraline (SEP-225289) Sumitomo...
BioCentury | Aug 3, 2018
Clinical News

Sunovion's high-dose dasotraline meets primary in Phase III for binge eating disorder

...of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said the once-daily 6 mg dose of dasotraline (SEP-225289...
...PDUFA date is Aug. 30. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Dasotraline (SEP-225289...
...Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Status: Phase III data Milestone: NA Sandi Wong dasotraline (SEP-225289) Sumitomo...
BioCentury | Mar 22, 2018
Strategy

Janssen’s virtual discovery

In the latest example of how AI can accelerate drug discovery, Janssen has shown it can use machine learning to create virtual drug screens that outperform conventional assays. The most promising application may be in...
BioCentury | Feb 23, 2018
Financial News

Celularity unveils size of series A

...the time, Celularity said it had a portfolio of immuno-oncology and regenerative therapies (see BioCentury, Sep...
BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / metabolic disease

...INDICATION: Diabetes In vitro and mouse studies suggest inhibiting SEPP1 could help treat diabetes. Screening of...
...assays identified a mAb that bound the first histidine-rich region of human SEPP1 and inhibited SEPP1...
...models of diabetes, and identifying small molecule or peptide inhibitors of SEPP1. TARGET/MARKER/PATHWAY: Selenoprotein P plasma 1 (SEPP1; SeP...
BioCentury | Oct 20, 2017
Clinical News

FDA approves sNDA for Sunovion's Aptiom

...FDA approved an sNDA for Aptiom eslicarbazepine acetate (BIA 2-093, SEP-0002093) from the Sunovion Pharmaceuticals Inc...
...Japan Product: Aptiom (Zebinix - EU) eslicarbazepine acetate (BIA 2-093, SEP-0002093) Business: Neurology Jennie Walters Aptiom BIA 2-093 eslicarbazepine acetate SEP-0002093 Bial-Portela...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...in June following an abandoned attempt to cap grants for more established senior investigators. Grants Sep...
...University , University of North Carolina , Drexel University and Florida State University . Grants Sep...
...and certificates automatically issued. The changes were mandated under the 21st Century Cures Act. Strategy Sep...
BioCentury | Sep 29, 2017
Clinical News

Sunovion submits NDA for dasotraline in ADHD

...subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) submitted an NDA to FDA for dasotraline (SEP-225289...
...eating disorder. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Dasotraline (SEP-225289) Business: Neurology Allison Johnson dasotraline SEP-225289 Sumitomo...
Items per page:
1 - 10 of 353